Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836423 | 0.87 | KMT2A (0.50) | SMN1; SMN2GAAALDH1A1MAPTKMT2A | |
| SCHEMBL23301730 | 0.85 | CES2 (0.45) | SMN1; SMN2LMNARAB9AGAAALDH1A1 | |
| SCHEMBL16584949 | 0.85 | RIPK1 (0.43) | SMN1; SMN2LMNARAB9AGAAALDH1A1 | |
| SCHEMBL29723949 | 0.85 | CES2 (0.45) | SMN1; SMN2LMNARAB9AGAAALDH1A1 | |
| SCHEMBL5251229 | 0.80 | KMT2A (0.50) | SMN1; SMN2LMNAGAAALDH1A1MAPT | |
| SCHEMBL2836425 | 0.80 | KMT2A (0.47) | SMN1; SMN2GAAALDH1A1MAPTKMT2A | |
| SCHEMBL5255790 | 0.79 | CES2 (0.43) | GAAALDH1A1RIPK1 | |
| SCHEMBL8323980 | 0.79 | ALB (0.47) | SMN1; SMN2RAB9AGAAALDH1A1KMT2A | |
| SCHEMBL8327982 | 0.79 | TSHR (0.49) | SMN1; SMN2LMNARAB9AALDH1A1MAPT | |
| SCHEMBL5254396 | 0.77 | MAPK1 (0.39) | GAAALDH1A1RIPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629294-B2 | Pyrazolopyrimidines | BAYER CROPSCIENCE LP (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7629294-B2 | Pyrazolopyrimidines | BAYER CROPSCIENCE LP (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7629294-B2 | Pyrazolopyrimidines | BAYER CROPSCIENCE LP (DE) | 2009-12-08 | — | — | US | disclosed |
| US-20050187224-A1 | Pyrazolopyrimidines | BAYER CROPSCIENCE AG (DE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187224-A1 | Pyrazolopyrimidines | P2RX5, P2RX4, P2RX1 | SMN1; SMN2 3995/4885LMNA 3788/4885RAB9A 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.